This cross-sectional analysis examines trends through 2025 in the use of metabolic and bariatric surgery during a period of increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists.
Rohde et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: